Surgery Websites
Transplant Surgery »  Meet the Team »  Nephrology »  Flavio Vincenti, M.D.
Flavio Vincenti, M.D.

Flavio Vincenti, M.D.

Clinical Professor of Medicine and Surgery
Departments of Medicine and Surgery
Endowed Chair in Kidney Transplantation

Contact Information

Academic Office
(415) 353-8390
Fax: 415.353.8974
flavio.Vincenti@ucsfmedctr.org

Appointments
(415) 353-1888 Liver
(415) 353-1551 Kidney and Pancreas
Open Popup
  • American University Medical Center of Beirut, BS  - 1971
  • Universite Saint-Joseph Faculty of Medicine, MD - 1975
  • Internal Medicine Residency: American University of Beirut Medical Center
  • Fellow in Nephrology, Emory University School of Medicine, Atlanta, Georgia, July 1, 1973 - June 30, 1975
  • Research Fellow, National Kidney Foundation, July 1, 1974 - June 30, 1975
  • Fellow in Cardiovascular Research Institute (Nephrology) University of California, San Francisco, July 1, 1975 - June 30, 1976
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Nephrology - Subspecialty
  • Chronic Kidney Disease
  • End Stage Renal Disease (Kidney Failure)
  • Internal Medicine
  • Kidney Transplantation
  • Living Kidney Donor Transplantation
  • Pancreas Transplantation
  • Transplant Nephrology
  • Transplant Nephrology

Dr. Flavio Vincenti, a kidney and pancreas transplant specialist, is board certified in internal medicine and nephrology. He came to UCSF Medical Center in 1975 for a transplant nephrology fellowship and was appointed a member of the kidney transplant team.

His memberships in professional organizations include the American Society of Nephrology, American Society of Transplantation, International Society of Nephrology and Transplantation Society. He is a co-leader of the kidney section of the Immune Tolerance Network for kidney transplantation. In addition, he is on the editorial board of the American Journal of Kidney Diseases and Graft.

In 1978, Vincenti was one of the authors of an article in the New England Journal of Medicine about the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and author on the use of anti interleukin 2 receptor monoclonal antibodies. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

Most recent publications from a total of 96
  1. Busque S, Vincenti FG, Tedesco Silva H, O'Connell PJ, Yoshida A, Friedewald JJ, Steinberg SM, Budde K, Broeders EN, Kim YS, Hahn CM, Li H, Chan G. Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. Transplant Direct. 2018 Sep; 4(9):e380. View in PubMed
  2. Webber AB, Tatapudi V, Maw TT, Peralta C, Leung JCY, Vincenti F. Nuclear Factor of Activated T Cell-regulated Cytokine Gene Expression for Adjustment of Tacrolimus in Kidney Transplant Recipients: A Randomized Controlled Pilot Trial. Transplant Direct. 2018 Jul; 4(7):e369. View in PubMed
  3. Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol. 2018 May 11. View in PubMed
  4. Vincenti F, Budde K, Merville P, Shihab F, Peddi VR, Shah M, Wyburn K, Cassuto-Viguier E, Weidemann A, Lee M, Flegel T, Erdman J, Wang X, Lademacher C. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Am J Transplant. 2018 May 09. View in PubMed
  5. Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Yang L, Medina Pestana J, Larsen CP. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT. Clin Transplant. 2018 Feb 20. View in PubMed
  6. Sigdel TK, Nguyen M, Dobi D, Hsieh SC, Liberto JM, Vincenti F, Sarwal MM, Laszik Z. Targeted Transcriptional Profiling of Kidney Transplant Biopsies. Kidney Int Rep. 2018 May; 3(3):722-731. View in PubMed
  7. Wojciechowski D, Chandran S, Yang JYC, Sarwal MM, Vincenti F. Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience. Clin Transplant. 2017 Sep; 31(9). View in PubMed
  8. Tang Q, Vincenti F. Transplant trials with Tregs: perils and promises. J Clin Invest. 2017 Jun 30; 127(7):2505-2512. View in PubMed
  9. Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. Kidney Int Rep. 2017 Sep; 2(5):800-810. View in PubMed
  10. Vincenti F. Belatacept: the challenges with transformational drugs. Transl Androl Urol. 2017 Apr; 6(2):341-342. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Flavio Vincenti, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

Site Directory
    X